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Abstract: b-Lactamases threaten the clinical use of carbape-
nems, which are considered antibiotics of last resort. The
classical mechanism of serine carbapenemase catalysis pro-
ceeds through hydrolysis of an acyl-enzyme intermediate. We
show that class D b-lactamases also degrade clinically used 1b-
methyl-substituted carbapenems through the unprecedented
formation of a carbapenem-derived b-lactone. b-Lactone
formation results from nucleophilic attack of the carbapenem
hydroxyethyl side chain on the ester carbonyl of the acyl-
enzyme intermediate. The carbapenem-derived lactone prod-
ucts inhibit both serine b-lactamases (particularly class D) and
metallo-b-lactamases. These results define a new mechanism
for the class D carbapenemases, in which a hydrolytic water
molecule is not required.
The hydrolysis of carbapenem antibiotics by b-lactamases
(i.e., carbapenemases) represents a major threat to clinically
important antibiotics of last resort.[1, 2] The classical mecha-
nism of the serine carbapenemases proceeds through a two-
step pathway involving the formation of an acyl-enzyme
intermediate, which is then hydrolyzed by a nucleophilic
water molecule.[3] All clinically used carbapenem antibiotics
have a 6-hydroxyethyl side chain, the presence of which is
proposed to disrupt the hydrolysis step.[4–6] We show that the
class D b-lactamases employ a previously unidentified mech-
anism for carbapenem degradation in which a b-lactone is
formed (Figure 1A). We provide evidence that lactone
formation occurs through a mechanism in which the hydroxy
group of the hydroxyethyl side chain acts as a nucleophile in
place of the water molecule required for hydrolysis.
While characterizing the carbapenemase activity of the
class D serine b-lactamase (SBL) OXA-48 (arguably one of
the most clinically important carbapenemases)[7] with the carbapenem ertapenem (Figure S1 in the Supporting Infor-
mation), we observed two major (and two minor) products by
NMR spectroscopy (Figure 1B). The proton spectrum of one
major product was identical to that observed from the
hydrolysis of ertapenem by the metallo-b-lactamase (MBL)
New Delhi MBL-1 (NDM-1; Figure 1B). Further NMR
analyses indicated that this corresponds to the anticipated
hydrolysis product with the pyrroline ring present as the D1
tautomer (Table S1–S3 in the Supporting Information); we
propose that the configuration at C-2 is S based on NOESY
spectra and coupling constant analysis (Figures S2,S3).
Chemical shift assignments for the other major product
differed substantially in the region corresponding to the
hydroxyethyl side chain (Tables S4,S5). Further analyses led
to the proposal that this product contains a b-lactone, in which
the oxygen derived from the hydroxyethyl side chain is
covalently bonded to the carbonyl originating from the
Figure 1. A) Major carbapenem-derived products formed by b-lactam-
ases. The C-2 stereochemistry of the products may depend on the
particular enzyme. B) NMR spectra (600 MHz) showing the different
product profiles of ertapenem (1 mm) with NDM-1 (5 mm) or OXA-48
(5 mm). Note that the minor peaks represent products with an
assigned R configuration at C-2 (indicated with a prime symbol; see
main text and Figures S2–S5).
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carbapenem b-lactam ring (Figure 1A). The chemical shift
assignments for this product resemble those of known b-
lactones (Table S6). Like the major hydrolysis product, the
major lactone product is observed as the D1 tautomer
(Tables S4, S5), and is proposed to have an S configuration
at C-2 (Figures S4, S5). Notably, b-lactone formation was
observed when ertapenem was incubated with Escherichia
coli expressing OXA-48 (Figure S6).
The ertapenem-derived lactone and hydrolysis products
were isolated by HPLC (Figure S7) and characterized by
NMR (Figures S8–S15) and MS (Figure S16). The infrared
spectrum of the lactone product showed a new peak at
1809 cm@1 (Figure S17), which is consistent with a b-lactone
carbonyl.[8, 9] The lactone product also behaved as expected
with respect to reaction with nucleophiles (Figure S18,
Table S7).
In addition to these major products, lower levels of other
species were observed in the reaction mixture (Figure 1B).
Further NMR analyses led to their assignment as stereoiso-
mers of the major lactone and hydrolysis products
(Tables S3,S5). The minor products were assigned as having
an R configuration at C-2, but are otherwise the same as the
2S-configured lactone and hydrolysis products (Figures S2–
S5).
A time-course analysis monitoring the relative levels of
the ertapenem OXA-48 products suggested that both lactone
and hydrolysis products are formed enzymatically (Fig-
ure S19). While the assigned 2S-configured lactone product
predominates at later time points, the assigned 2R-configured
lactone is observed at relatively higher levels at early time
points. Incubation of the purified lactone and hydrolysis
products in buffered D2O showed non-enzymatic intercon-
version between the 2S and 2R diastereomers (Figure S20).
Therefore, the greater amount of the 2S diastereomers
observed in our initial spectra (Figure 1B) may reflect their
relative thermodynamic stabilities, whereas the 2R diastereo-
mers may represent a greater proportion of the nascent
enzymatic products.
The generality of b-lactone formation by OXA-48 was
next examined. In addition to ertapenem, b-lactone formation
was observed for meropenem, biapenem, and doripenem
(Figures S21-S24, Tables S8–S16). However, no b-lactone
formation was observed within detection limits for imipenem
and panipenem (Figures S25, S26, Tables S17–S20). The prod-
uct profiles of OXA-10 and OXA-23 with these carbapenems
are similar (Figures S21–S26). Therefore, within the limits of
detection, b-lactone formation appears to require the pres-
ence of a 1b-methyl substituent. While the MBL carbapene-
mases NDM-1, CphA, and L1 demonstrated carbapenemase
activity, no b-lactone formation was observed (Figures S21–
S26). Similarly, only hydrolysis products were observed with
the class A carbapenemase SFC-1 (Figures S21–S26).[10]
b-Lactone formation likely results from intramolecular 4-
exo-trig cyclization[11] of the hydroxyethyl oxygen onto the
ester carbonyl of the acyl-enzyme intermediate (Figure 2A).
Crystallographic studies of OXA-1 with doripenem[12] and of
OXA-58 with a 6a-hydroxymethyl penicillin[13] indicate that
the catalytically important carbamylated lysine residue inter-
acts with the hydroxyethyl side chain (Figure S27). Further-
more, the hydroxyethyl hydroxy group can adopt an orienta-
tion suitable for nucleophilic attack onto the ester carbonyl
(i.e., the Bgrgi–Dunitz trajectory),[14] with the carbamylated
lysine apparently positioned to act as a general base.[12,13]
Although this conformation of the hydroxyethyl side chain
was not observed in related crystal structures (Figure S27),
Figure 2. A) Proposed outline mechanisms for carbapenem hydrolysis
and lactone formation. KCX labels the carbamylated lysine residue,
which acts as a general base. Lactone formation was only observed for
carbapenems bearing a 1b-methyl group (blue). The timing of the
imine tautomerization is not defined, but likely occurs (in part) prior
to fragmentation of the acyl-enzyme complex. It is unclear based on
the products observed whether a particular configuration at C-2
predominates. B) DFT non-covalent interaction isosurfaces showing
unfavorable steric interactions between the carbapenem 1b-Me and
hydroxyethyl groups, which are alleviated in the corresponding 1b-H
system. Reduced density gradient isosurface s = 0.5, 1(r) signl2 (e/au)
color scale runs from @0.02 (blue) to 0.02 (red). C) Representations of
two major conformations of the hydroxyethyl group observed during
MD simulation of the OXA-1 doripenem complex;[12] the upper
conformation appears to be more favorable for b-lactone formation.
Note that the doripenem thioether side chain and serine backbone are
represented as methyl groups.
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these structures depict enzymes in which the lysine is not
carbamylated (e.g., due to low pH or mutations).[5,15, 16]
Kinetic studies of OXA enzymes show that the kcat values
for 1b-methyl-substituted carbapenems tend to be 10–100-
fold less than for those with a 1b-proton.[17, 18] Non-covalent
interaction plots indicate that the 1b-methyl group may
interact sterically with the hydroxyethyl group in the acyl-
enzyme complex, which is largely alleviated in the corre-
sponding 1b-proton system (Figure 2B). Molecular dynamics
simulations (100 ns) of the acyl-enzyme complex derived
from OXA-1 and doripenem[12] also suggest that the con-
formation of the hydroxyethyl group is influenced by the 1b-
substituent, with the system bearing a 1b-proton showing
more flexibility (Tables S21–S23, Figures S28–S31). Notably,
in the MD simulations, the 1b-methyl system initially alter-
nates between two conformations (Figure 2C), one of which
appears to be consistent with that expected for b-lactone
formation (Figure S27).
We propose that the 1b-methyl group destabilizes the
conformation(s) of the hydroxyethyl side chain required for
hydrolysis of the acyl-enzyme complex. Consequently, the
acyl-enzyme complexes of 1b-methyl carbapenems with OXA
enzymes are more resistant to hydrolysis than are those
derived from carbapenems without a 1b-methyl group. The
class D b-lactamases have apparently, at least in part, over-
come this inhibition by catalyzing lactone formation. How-
ever, lactone formation may only represent a competitive
pathway if hydrolysis is disfavoured (i.e., by the 1b-methyl
group), thus explaining why only hydrolysis is observed for
carbapenems without a 1b-methyl group.
Since the lactone products are isomeric with b-lactams, it
was considered that they may interact with b-lactamases and
penicillin-binding proteins (PBPs). Indeed, the ertapenem-
derived lactone was hydrolyzed by SBLs with carbapenemase
activity (SFC-1, OXA-23, and OXA-48; Figure 3A); by
contrast, no lactone hydrolysis was observed with carbape-
nemase MBLs (NDM-1, CphA, and L1; Figure 3A). Acyla-
tion of some SBLs, such as OXA-10, by the ertapenem-
derived lactone was observed by MS (Figure 3B, Figure S34).
However, the lactone did not show antibiotic activity at the
levels tested against E. coli (Figure S35), nor was acylation
observed for the non-essential PBP-5 from E. coli (Fig-
ure S34).
The ertapenem-derived lactone inhibited both SBLs and
MBLs when tested at high concentrations (Figure 3C).
Class D b-lactamases were inhibited particularly strongly,
with IC50 values of 790 nm, 1.2 mm, and 940 nm obtained for
OXA-10, OXA-23, and OXA-48, respectively (Figure 3D,
Figure S36). However, the potency of the lactone was
relatively low compared to ertapenem (IC50 values of
1.9 nm, 65 nm, and 10 nm for OXA-10, OXA-23, and OXA-
48, respectively; Figure 3D, Figures S36, S37). The observed
inhibition of some MBLs is interesting, given the lack of
clinically used inhibitors for these enzymes.[19]
The degradation of carbapenems through b-lactone for-
mation represents a new mechanism for the carbapenemases.
Carbapenems are potent inhibitors of many PBPs and SBLs,
with which they rapidly react to form an acyl-enzyme
complex; this complex is stabilized due to disruption of the
“hydrolytic water” by the hydroxyethyl side chain. Thus, the
results presented here suggest that, in the case of clinically
important 1b-methyl carbapenems, the class D b-lactamases
may have evolved to overcome this disruption, in part by
promoting lactone formation. Although the lactones repre-
sent a type of product inhibition, their potency is less than that
of the parent carbapenems. It will be of interest to see
whether other mechanisms for fragmentation of the acyl-
enzyme ester evolve.
Avibactam, which was recently introduced as the first
clinically used non-b-lactam-containing b-lactamase inhibitor,
works through a reversible acylation mechanism.[20] The
observation that carbapenem-derived lactones acylate serine
b-lactamases suggests that new classes of b-lactamase inhib-
itors based on lactones are possible. In this regard, it is
notable that the b-lactone orlistat is an important medicine,[21]
and that lactone antibiotics (e.g., obafluorin)[8] and inhibitors
of serine proteases (and lactam derivatives thereof)[22, 23] have
been reported. Carbapenem-derived b-lactones thus repre-
sent a novel scaffold for b-lactamase inhibition that, with
Figure 3. A) Extent of hydrolysis of the ertapenem lactone by a panel
of carbapenemases (1 h, 0.5 mm lactone, 5 mm enzyme). B) Mass
spectra showing acylation of OXA-10 (1 mm) by ertapenem (100 mm)
and ertapenem lactone (100 mm) after 30 min. C) Inhibitory activity of
ertapenem lactone (1 mm, 0.5 mm, 0.1 mm) against a panel of SBLs
and MBLs. D) Comparison of the inhibitory activity of ertapenem and
ertapenem lactone against OXA-10.
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optimization, may prove comparable in potency to the
carbapenems.
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